arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Travere Therapeutics, Inc.

TVTX
$48.89 ▼ -3.59 (-6.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Travere Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.6B
Dividend Yield —
Revenue Growth 36.2% ↘
Op. Margin -30.3% ↘
ROIC -275.0% ↘
FCF / Share $1.04 ↗
Trailing P/E —
Price / Book 207.1x
FCF Yield 2.1%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$224.56M
↑ +36.2% —
Net Income Profit after all expenses
$-52.34M
↓ -50.4% —
Operating Margin Operating profit as % of sales
-30.3%
↓ -1400.7% 13th
FCF / Share Free cash flow per share
$1.04
↑ +67.1% —
Long-Term Debt Long-term obligations
$46.00M
↓ -49.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
29
Returns ↑
27
Financial Health ↑
34
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 65 quarters